Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17103375 | 0.82 | — | — | |
| SCHEMBL17092106 | 0.82 | — | — | |
| SCHEMBL17103397 | 0.79 | — | — | |
| SCHEMBL14989748 | 0.73 | — | — | |
| SCHEMBL1491767 | 0.68 | MALT1 (0.38) | MALT1 | |
| SCHEMBL790674 | 0.67 | — | — | |
| SCHEMBL790303 | 0.67 | — | — | |
| SCHEMBL16457493 | 0.66 | KIF11 (0.47) | — | |
| SCHEMBL4695390 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL6192480 | 0.66 | MALT1 (0.36) | MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | claimed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | claimed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | claimed |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | HISTOGEN, INC. | 2021-09-09 | — | — | US | claimed |
| EP-3814327-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | Histogen, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| US-9855267-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-01-02 | — | — | US | claimed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | claimed |
| US-9783488-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-10-10 | — | — | US | claimed |
| US-9617259-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-04-11 | — | — | US | claimed |
| CN-103649073-A | 17alpha-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2014-03-19 | — | — | CN | claimed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | claimed |
| CN-103596937-A | Substituted benzamide derivatives | HOFFMANN LA ROCHE | 2014-02-19 | — | — | CN | claimed |
| WO-2014014900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2014-01-23 | — | — | WO | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| WO-2012168265-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | claimed |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-12-13 | — | — | US | claimed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | claimed |
| US-5401763-A | Derivatives of arylacetic esters displaying high fungicidal activity | Ministero Dell `Universita` e Della Ricerca Scientifica e Technologica (IT) | 1995-03-28 | — | — | US | claimed |
| EP-0611760-A1 | Derivatives of arylacetic esters displaying high fungicidal activity | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1994-08-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | MALT1 2636/4885 |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CASP1, CASP3, CASP6 | MALT1 276/4885 |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | NPY4R, PER2, NPY1R | MALT1 1452/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | MALT1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.